<DOC>
	<DOCNO>NCT00003771</DOCNO>
	<brief_summary>RATIONALE : Hormone replacement therapy effective relieving symptom menopause . It yet know hormone replacement therapy increase risk breast cancer recurrence woman previously treat early stage breast cancer . PURPOSE : Randomized phase III trial determine risk breast cancer recurrence woman previous early stage breast cancer receive hormone replacement therapy menopause symptom .</brief_summary>
	<brief_title>Hormone Replacement Therapy Risk Breast Cancer Recurrence Women With Previous Early Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate safety hormone replacement therapy , term risk recurrence , woman previously treat , nonrecurrent stage 0-II breast cancer . - Compare regimen vs non-hormonal symptomatic treatment , term quality life risk death , patient population . OUTLINE : This randomize , open-label , multicenter study . Patients stratify center , prior hormone replacement therapy diagnosis , concurrent tamoxifen therapy . Patients randomize one two treatment arm . - Arm I : Patients receive one following : Women intact uterus whose last menstrual bleeding occur within 2 year receive continuous oral cyclic estradiol-norethindrone combination comprise estradiol day 1-12 , estradiol plus norethindrone day 13-22 , estradiol day 22-28 . Women intact uterus whose last menstrual bleeding occur 2 year prior study receive continuous daily oral estradiol-norethindrone combination . Women hysterectomy receive continuous daily oral estradiol . - Arm II : Patients receive one non-hormonal therapy ( e.g. , clonidine , beta blocker , psychological support , physical exercise , acupuncture ) . Treatment arm continue 2 year absence disease progression . Patients may continue randomize treatment regimen discretion treat physician . Quality life assess 3 time study every two year thereafter . Gynecological health assess 3 month , 6 month , one year study annually least 5 year . Breast cancer assess every 6 month 3 year annually thereafter discretion treat physician . PROJECTED ACCRUAL : A total 1,300 patient accrue study within 5-6 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History stage 0II breast cancer 4 involve axillary node nodal status number node investigate know No current evidence disease Hormone receptor status : Positive , negative , unknown PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Menopausal perimenopausal Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No active liver disease Renal : Not specify Cardiovascular : No prior concurrent deep vein thrombosis No hereditary trait deep vein thrombosis No prior concurrent cerebral stroke No prior concurrent coronary disease Other : No prior malignancy except basal cell skin cancer carcinoma situ cervix No porphyria No serious disease would prevent compliance greatly limit life expectancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : Prior hormone replacement therapy ( HRT ) allow stop 4 week breast cancer diagnosis least 3 month prior study No prior HRT initiate breast cancer diagnosis No concurrent hormonal therapy breast cancer except tamoxifen toremifene Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No prior randomization trial compare effect chemotherapy bilateral oophorectomy premenopausal woman</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>menopausal symptom</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>